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Susanne Roosing,1,2,27,* and Alison J. Hardcastle3,4,5,27SummaryThe cause of autosomal-dominant retinitis pigmentosa (adRP), which leads to loss of vision and blindness, was investigated in families
lacking a molecular diagnosis. A refined locus for adRP on Chr17q22 (RP17) was delineated through genotyping and genome
sequencing, leading to the identification of structural variants (SVs) that segregate with disease. Eight different complex SVs were char-
acterized in 22 adRP-affected families with >300 affected individuals. All RP17 SVs had breakpoints within a genomic region spanning
YPEL2 to LINC01476. To investigate the mechanism of disease, we reprogrammed fibroblasts from affected individuals and controls into
induced pluripotent stem cells (iPSCs) and differentiated them into photoreceptor precursor cells (PPCs) or retinal organoids (ROs). Hi-C
was performed on ROs, and differential expression of regional genes and a retinal enhancer RNA at this locus was assessed by qPCR. The
epigenetic landscape of the region, and Hi-C RO data, showed that YPEL2 sits within its own topologically associating domain (TAD),
rich in enhancers with binding sites for retinal transcription factors. The Hi-C map of RP17 ROs revealed creation of a neo-TAD with
ectopic contacts between GDPD1 and retinal enhancers, and modeling of all RP17 SVs was consistent with neo-TADs leading to ectopic
retinal-specific enhancer-GDPD1 accessibility. qPCR confirmed increased expression of GDPD1 and increased expression of the retinal
enhancer that enters the neo-TAD. Altered TAD structure resulting in increased retinal expression of GDPD1 is the likely convergent
mechanism of disease, consistent with a dominant gain of function. Our study highlights the importance of SVs as a genomic mecha-
nism in unsolved Mendelian diseases.Introduction
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The most common form of IRD is retinitis pigmentosa
(RP [MIM: 268000]), which is genetically heterogeneous,
with a prevalence of 1 in 4,000.3 RP is defined as a
retinal degeneration that primarily affects rod photore-
ceptors, resulting in night blindness and progressive
loss of peripheral vision, often progressing into the
central retina and affecting cone photoreceptors,
leading to severe visual impairment or blindness (see
‘‘Nonsyndromic Retinitis Pigmentosa Overview’’ in Web
Resources). Autosomal-dominant RP (adRP) accounts
for 25%–40% of cases, depending on the population
studied, and has been associated with mutations
in 30 genes, including CA4 (MIM: 114760) on
Chr17q23.1 (RP17 [MIM: 600852])(see ‘‘RetNet’’ in Web
Resources).4,5 Following initial publications defining
this locus6,7 a variant in CA4 was implicated as the cause
of adRP in families of South African origin, however
pathogenicity of the reported variant has been ques-
tioned because it has a population frequency of 4% in
healthy controls in northern Sweden.8–10 Subsequently
reported CA4 variants in individuals with RP were iden-
tified by targeted Sanger sequencing and do not fully
exclude variants in other genes as a cause of disease
(Table S1).
We investigated the cause of adRP in unsolved families,
including the first pedigree (GC1, referred to as UK1)
drawn up at Moorfields Eye Hospital over 35 years ago
and the original Dutch family (W97-079, referred to as
NL1) that showed linkage to the RP17 locus but lacked a
mutation in CA4.7
Here, we report identification and characterization of
complex SVs on Chr17q22, through whole-genome
sequencing (WGS), as the genomic cause of adRP at
the RP17 locus in a large number of families, including
the families of South African origin. To explore a
convergent mechanism of disease, we investigated
the effect of RP17 SVs on three-dimensional (3D)
chromatin organization that results in the compart-
mentalization of the genome into topologically associ-
ating domains (TADs) and the epigenetic landscape of
the region. TADs are chromatin domains within the
genome that facilitate enhancer promoter contacts
within the nuclear 3D space.11 Disruption of TAD
structures can lead to loss of chromosomal contact
between regulatory regions and their target genes or
the formation of novel active domains with ectopic
contacts occurring between regulatory regions and a
new target gene, resulting in pathogenic alterations
in gene expression.12–15 We demonstrate that altered
TAD structure at the RP17 locus leads to ectopic
retinal enhancer-gene interactions, consistent with a
dominant gain of function. Our study highlights the
pathogenicity of SVs that alter 3D chromatin organiza-
tion and gene expression by rearranging TAD structures
and the need to revisit rare Mendelian diseases for which
genes and variants have not been substantiated in other
cohorts.The AmericanMaterial and Methods
Study Cohort
The study was approved by the medical ethics committee of the
ErasmusMC Rotterdam, Radboudumc Nijmegen, and Moorfields
Eye Hospital and was performed in accordance with the principles
of the World Medical Association Declaration of Helsinki.
Informed consent was obtained from all participants or their legal
representatives.
Genetic Analyses
We performed SNP genotyping for index families NL1 and UK1
to define and refine the RP17 locus. Genomic DNA from affected
individuals and their family members was analyzed by whole-
exome sequencing (WES) and WGS. Sequence data was aligned
to the Human Reference Genome build hg19. Variants were
prioritized on the basis of a minor allele frequency (MAF) %
0.0001 in gnomAD. SVs were called with ExomeDepth, Manta
Structural Variant Caller, Canvas Copy Number Variant Caller,
and Control-FREEC. Details of genotyping, sequencing, and
analysis pipelines are provided in the Supplemental Material
and Methods.
Characterization and Validation of Structural Variants
SV breakpoint junctions were PCR amplified and validated with
Sanger sequencing. Primer sequences and coordinates are listed
in Table S2. SV breakpoint regions were assessed for the presence
of microhomology and repetitive elements. To validate a tripli-
cated region for UK-SV6, we performed quantitative real-time
PCR (qPCR) on genomic DNA from affected individuals from fam-
ily UK13 and unaffected controls (Supplemental Material and
Methods).
Clinical Analysis
Available clinical notes of cases for the pedigrees identified at Rad-
boudumc, Moorfields Eye Hospital, University of Cape Town, and
McGill University Health Centre were reviewed, as well as detailed
retinal imaging, fundus autofluorescence, and optical coherence
tomography. Age of onset is defined as the age at which symptoms
were first experienced.
Interrogation of the Genomic Region
We interrogated chromatin and genome regulation datasets to
explore the epigenomic landscape of the region. Available datasets
were obtained and analyzed via the UCSC genome browser (details
of datasets used are provided in Supplemental Material and
Methods).
Reprogramming Fibroblasts into iPSCs and
Differentiation into Photoreceptor Progenitor Cells and
3D Retinal Organoids
Fibroblasts were cultured from skin biopsies of two individuals
with NL-SV1, one individual with UK-SV2, and five anonymous
control individuals. Cell lines were reprogrammed into induced
pluripotent stem cells (iPSCs) and differentiated into photore-
ceptor progenitor cells (PPCs) following the previously described
60 day protocol (Supplemental Material and Methods).16,17 3D
retinal organoids (ROs) were differentiated for UK-SV2 and
controls, as previously described (Supplemental Material and
Methods).18Journal of Human Genetics 107, 802–814, November 5, 2020 803
Preparation of Low Input Hi-C Libraries (Low-C)
Hi-C was performed on UK-SV2 and control 3D ROs via a low
input protocol (Low-C) with few modifications (Supplemental
Material andMethods).19 Two libraries per sample were sequenced
for 200 million fragments in a 100 bp paired-end run on a Nova-
Seq 6000 (Illumina). Paired-end sequencing data was processed
via Juicer20 and the Hi-C maps were created with a bin size with
10 kb resolution. Further information about the bioinformatics
pipeline is detailed in Melo et al., 2020.21Expression Analysis of Genes and Enhancer RNA within
the RP17 Locus
To assess expression of genes, we performed qPCR for different hu-
man tissues, including retina (Table S3 and Supplemental Material
and Methods). Single-cell RNA sequencing data of human22 and
primate23 retinal cell types were obtained and visualized via the
Broad Institute Single Cell Portal (Supplemental Material and
Methods).
cDNA was synthesized from total RNA extracted from PPCs,
ROs, and fibroblasts. Differential expression of genes implicated
in the SVs, and control housekeeping and retinal progenitor
genes, was assessed by qPCR (Table S3 and Supplemental Material
and Methods). We designed primers to the enhancer region con-
taining multiple retinal transcription factor binding sites impli-
cated in all SVs to analyze targeted enhancer RNA expression by
qPCR (Table S3 and Supplemental Material and Methods).Results
Refinement of the RP17 Locus in Two Unrelated adRP-
Affected Families
The affected haplotype for a Dutch adRP-affected family
(NL1) (Figure 1A) was previously mapped to a 7.18 Mb
region spanning the RP17 locus on chromosome 17.7
The RP17 locus was refined to a 5.16 Mb interval by SNP
haplotyping in an extended pedigree (Figure 1D and
Supplemental Information). No rare coding or splice site
heterozygous variants (MAF % 0.0001) shared between
affected individuals were found through WES. Subse-
quently, WGS was performed, and similarly, no rare
candidate coding, splice site, intronic, or intergenic hetero-
zygous single-nucleotide variants were identified (Table S4
and Supplemental Information).
In parallel, WES and WGS were performed for affected
individuals from a genetically unexplained UK adRP-
affected family (UK1) (Figure 1B). This also failed to iden-
tify a rare causative variant; however, a disease-associated
haplotype on chromosome 17 was identified (Figure 1E,
Table S5, and Supplemental Information). Interrogation
of unsolved IRD sequence data generated through the UK
IRDC, UCL-Ex, NIHR-Bioresource, and Genomics England
identified other adRP probands that shared the same
haplotype of Chr17 SNVs and established this as a founder
haplotype in eleven additional UK adRP-affected families
(Figure 1C). The adRP locus was refined to a 4.4Mb interval
on Chr17q22 (Figure 1E). This genomic interval overlaps
the previously described RP17 locus in families of Dutch
and South African origin (Figure 1F).804 The American Journal of Human Genetics 107, 802–814, NovemA missense variant in CA4 [c.40C>T (p.Arg14Trp);
GenBank: NM_000717.4] was previously described as
the cause of adRP at the RP17 locus in families of South
African origin.8 No rare coding, intronic, or upstream
variants in CA4 were identified in the Dutch and UK
families.
Identification of Structural Variants within the RP17
Locus
Next, we analyzed genome and exome data for copy num-
ber variants and SVs (Supplemental Information). In family
NL1, WGS revealed a 226 kb duplication within the RP17
locus: chr17: 57,291,905_57,518,137dup (NL-SV1). This
SV involves two duplicated genes (GDPD1 [MIM: 616317]
and YPEL2 [MIM: 609723]), an intragenic microRNA
(MIR4729), and partial duplication of SMG8 (MIM:
613175) and the long non-coding RNA LINC01476.
The duplication creates a breakpoint junction (chr17:
g.57,518,137–57,291,905) specific for the mutated allele in
NL1 (Figures 2A, 2B, and S1), which was used to confirm
segregation of the SV with the adRP phenotype in this fam-
ily. No overlapping SVs in the RP17 locus were observed
in WES of ~7,500 individuals without retinal disease gener-
ated in-house at the Department of Human Genetics,
Radboudumc.
For the twelve UK RP17 founder haplotype fam-
ilies, WGS revealed a duplicated inversion: chr17:
57,456,098–57,468,960delins57,275,839_57,559,114inv
(UK-SV2) (Figure 2B). The SV was characterized, and
breakpoint junctions were validated (Figure S1 and Sup-
plemental Information). This SV involved four coding
genes (PRR11 [MIM: 615920], SMG8, GDPD1, and
YPEL2) and two non-coding RNA genes (MIR4729 and
LINC01476) (Figure 2B). UK-SV2 segregated with adRP
in all families for which DNA was available for analysis.
UK-SV2 was absent in WGS control genome data gener-
ated for 58,000 UK individuals (Genomics England).
Different Structural Variants within the RP17 Locus in
Multiple adRP-Affected Families
These data prompted us to investigate whether SVs were
present in the two original South African families (SA1
and SA2) that were linked to the RP17 locus
(Figure S2A).6,8 In addition, a Canadian adRP-affected fam-
ily (CA1) was also mapped to the RP17 locus (unpublished
data, Figure S2B). WGS was performed for affected individ-
uals from these families, and inversion duplication events
were identified in all samples analyzed (Figure 2C). In SA1
and SA2, an identical SV, SA-SV3, was revealed, suggesting
this is a founder variant in this population. SA-SV3 was
also found by breakpoint PCR in two additional families
of South African origin (SA3 and SA4), confirming the
founder effect (Figure S2A). In the Canadian family, a
different inversion duplication event was identified, CA-
SV4. SA-SV3 and CA-SV4 breakpoints were characterized
and validated (Figure S1), and segregation of the SVs with
the adRP phenotype was confirmed.ber 5, 2020
Figure 1. Mapping of the RP17 Locus in Two Unrelated Families
(A) Pedigree of Dutch NL1 family.
(B) Pedigree of UK1 family.
(C) Pedigrees of additional UK families with the founder haplotype onChr17q.WGS orWESwas performed in individuals highlighted in
blue or red, respectively.
(D) SNP haplotyping results for NL1. The refined RP17 locus (rs8078110–rs9910672) is shared by all affected individuals (n¼ 35) and not
present in unaffected individuals (n¼ 28, only individuals with recombination close to or refining the critical region are depicted) with a
maximum LOD score of 15.0. The horizontal numbers represent the number of individuals with this haplotype.
(E) UK founder haplotype refining the RP17 locus in UK families. Representative haplotypes from several unrelated families are shown
with affected (aff) individuals compared to an unaffected (unaff) individual. Black lines and arrows indicate recombination events.
Shared haplotype in individuals is shaded red.
(F) Overlap of refined RP17 loci in UK, NL, and previously described SA families.8Our data suggested that SVs at the RP17 locus are an
important cause of adRP. Therefore, WGS and WES data
for genetically unexplained adRP-affected families wereThe Americananalyzed for SVs within this locus. In four unrelated fam-
ilies of Dutch or UK origin, four additional unique com-
plex SVs were discovered (Figures 2D and S2C). ForJournal of Human Genetics 107, 802–814, November 5, 2020 805
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Figure 2. Overview of Structural Variants within the RP17 Locus in adRP-Affected Families
Breakpoints are indicated with dashed lines. Blue segments represent duplicated or triplicated regions, whereas inversions are high-
lighted in purple.
(A) Wild-type (WT) chromosomal organization.
(B) Structural variants identified in NL1 (NL-SV1) and UK founder haplotype families (UK-SV2).
(C) Structural variants identified in adRP-affected families that were previously linked to the RP17 locus; SA-SV38 and CA-SV4 (unpub-
lished data).
(legend continued on next page)
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individuals that had only undergone WES, we performed
WGS to determine the breakpoint junctions and identify
potential inversions or other SVs. In all families, break-
points were validated, and segregation analysis was per-
formed where possible. Triplication for UK-SV6 was
confirmed by qPCR in family UK13 (Figure S3 and Supple-
mental Information).
Details of all SVs identified in this study are shown in
Table S6, Figure 2, and Figure S4, and an overview of SV-
specific breakpoint junctions is shown in Figure S1. All
RP17 SVs share a common duplicated (or triplicated) re-
gion of 11.5 kb and harbor unique breakpoints disrupting
the genomic region spanning YPEL2 to LINC01476 (chr17:
57,499,214–57,510,765) (Figure S4).We analyzed all break-
point junction sequences to investigate the potential
mechanism(s) that created RP17 SVs. No single mecha-
nism could account for the RP17 SVs because a combina-
tion of (micro)homology-mediated repair and non-homol-
ogous end joining events were identified (Table S7 and S8,
Figure S5, and Supplemental Information).
Consistent Autosomal-Dominant Retinitis Pigmentosa
Phenotype for RP17-Affected Families
The SVs identified were fully penetrant in all families.
Available clinical data are presented in Table S9. Twenty-
four affected individuals from seventeen pedigrees were
evaluated. There is significant correlation of phenotype
across all genotypes with relatively mild disease, decreased
visual acuity, visual field constriction, nyctalopia, and slow
progression consistent with adRP. Many affected individ-
uals have preserved central visual function and acuity until
the 6th–7th decade. Foveal sparing and cystoid macular
edema were a common finding in individuals with UK-
SV2. On the basis of a small number of affected individuals
(n ¼ 2), UK-SV6 (with a triplicated SV) may be associated
with an earlier age of onset and more severe phenotype
(Figure S6).
Topologically Associating Domain Structure and
Epigenetic Landscape of the RP17 Genomic Region
All of the RP17 SVs lead to disruption of the genomic re-
gion spanning YPEL2 to LINC01476 (Figure 2E). SVs
that interfere with genome structure can have distinct ef-
fects on gene regulation depending on the type and
extent of the SV and landscape of the genomic region.15
TADs are separated by boundaries, regions of low chro-
matin interaction that insulate the regulatory activities
of neighboring TADs. The transcription factor CTCF
(CCTC-binding factor) typically binds in these regions
where it plays a pivotal role in the maintenance of bound-
aries. SVs can cause loss of function by disconnecting en-(D) Structural variants found in a cohort of unsolved adRP-affected fa
the genomic intervals for each SV used to analyze and annotate SV b
(E) Overview of all SV breakpoints identified in the RP17 locus. An ov
was identified (chr17: 57,499,214–57,510,765) and is highlighted by
partially shown for the purpose of this figure.
The Americanhancers from their target genes; however, disruption of
TAD structures and boundaries can also exert a gain-of-
function effect. Deletions, for example, can lead to the
fusing of two previously separated TADs (TAD-fusion), in-
versions can result in the exchange of regulatory material
between TADs (TAD-shuffling), whereas duplications can
give rise to the generation of novel domains, so-called
neo-TADs.12,13 In each case, SVs result in the generation
of ectopic contacts of enhancers with the promoters of
novel target genes resulting in aberrant gene activation.
The human limb malformations caused by SVs that alter
the CTCF-associated boundary of the WNT6/IHH/
EPHA4/PAX3 locus are a prominent example. The SVs
result in ectopic interactions between EPHA4 (MIM:
602188) limb enhancers and the neighboring develop-
mental genes that are normally insulated, driving ectopic
expression in the limb.14 Similarly, the deletion of a CTCF
site located between the Xist (MIM: 314670) and Tsix
(MIM: 300181) TADs on the X chromosome resulted in
a novel domain by fusion of the adjacent TADs (fused-
TAD).24 As a consequence, previously insulated en-
hancers activated genes in the adjacent TAD, leading to
the dysregulation of these genes.
Hi-C data were not available for human retina, and
therefore, we generated Hi-C maps of control human 3D
ROs to obtain maps of the chromatin organization of
our region of interest. Hi-C revealed a structured domain
containing YPEL2 (YPEL2 TAD) flanked by less structured
neighboring domains (Figure 3A). CTCF binding is pre-
sent on both boundaries (Figure 3B) supporting the TAD
structure at this locus. CTCF ChIA-PET data highlighted
interactions between the CTCF binding sites at the 50
and the 30 boundary of the YPEL2 TAD (Figure S7B).
Assay for transposase-accessible chromatin using seqenc-
ing (ATAC-seq) data from human retina show that the
chromatin in the YPEL2 TAD is accessible, and H3K27Ac
ChIP-seq data revealed that there are several active en-
hancers located within the YPEL2 TAD that are expected
to drive YPEL2 expression in the retina (Figure 3B).25
Importantly, the YPEL2 TAD harbors two regions of active
enhancers with binding sites for transcription factor (TFs)
known to be required for photoreceptor function,
including NRL, CRX, and OTX2 (Figure 3B). NRL is a TF
that is preferentially expressed in rod photoreceptors.
These TF binding sites correlated with H3K27Ac and
ATAC-seq peaks in retina. The published GeneHancer data-
set shows that these regulatory elements have interactions
with the YPEL2 promoter (Figure S7C).26 Collectively, these
analyses revealed that YPEL2 is located within an active
compartment that contains retinal-specific enhancers
(Figure 3C).milies; NL-SV5, UK-SV6, UK-SV7, and UK-SV8. Letters A–AI depict
reakpoints.
erlapping genomic region that is duplicated or triplicated in all SVs
a light blue vertical bar. The size of DHX40 is reduced, and CLTC is
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Figure 3. YPEL2 is Located within a Structured Active Compartment that Contains Retinal-Specific Enhancers
(A) The TAD landscape of the genomic region disrupted by the RP17 SVs. Hi-C map of control retinal organoids revealed a structured
domain containing YPEL2.
(B) YPEL2 TAD boundaries correspond with CTCF sites identified in human retina. Analysis of RNA-seq and assay for transposase-
accessible chromatin using seqencing (ATAC-seq) data across the YPEL2 region shows YPEL2 retinal expression and an accessible chro-
matin configuration. Analysis of H3K27Ac ChIP-seq data in the same region revealed several active enhancers located within the YPEL2
TAD, which are enriched for retinal transcription factor binding sites, includingNRL, CRX, andOTX2.25 These enhancers were located 50
of the CTCF boundary site within LINC01476.
(C) Schematic representation of the YPEL2 TAD structure.Expression of YPEL2 and GDPD1
Expression of YPEL2 and GDPD1 was assessed by qPCR
in multiple healthy human tissues, including retina
(Figure S8). YPEL2 is ubiquitously expressed in the tis-
sues studied, including retina, with highest relative
expression in brain. Single-cell retina RNA-seq datasets
revealed YPEL2 is expressed at higher levels in rod photo-
receptor cells, which is the primary cell type affected in
retinitis pigmentosa, compared to cone photoreceptors
(Figure S8).23 GDPD1 is detected at low expression in808 The American Journal of Human Genetics 107, 802–814, Novemall tissue types but has higher expression in testis and
the brain. These data support the hypothesis that
YPEL2 expression is regulated by retinal enhancers
within the YPEL2 TAD.RP17 SVs Create New Topologically Associating
Domains and Ectopic Enhancer-Gene Interactions
Using the wild-type retinal organoid Hi-C map, we
modeled the TAD boundaries, CTCF site orientation, and
retinal TF binding site positions for each unique RP17 SVber 5, 2020
Figure 4. RP17 SVs Create Novel Domains (neo-TADs) and Hyper-activation of Retinal Enhancers
(A) Schematic modeling of the genome architecture spanning the RP17 region using Hi-C maps. The wild-type Hi-C map derived from
neuronal tissue shows a TAD with CTCF boundaries containing YPEL2 and retinal enhancers, flanked by unstructured domains. TAD
models of NL-SV1 and UK-SV2 (dotted vertical lines represent SV breakpoints) predict the formation of neo-TADs and ectopic interac-
tions of the retinal enhancer with GDPD1.
(B) Hi-C performed on retinal organoids (ROs) derived from control (top) and RP17 UK-SV2 individuals (bottom) (10 kb resolution; raw
count map). The chromatin organization in control ROs shows the YPEL2 TAD (indicated by dashed lines). Two novel domains (neo-
TAD 1 and 2) are visible in the UK-SV2 ROs, and neo-TAD 2 allows ectopic retinal enhancer contacts to GDPD1 and SMG8. The dashed
circle indicates the strong chromatin contact between retinal enhancers and the GDPD1 promoter.
(C) qPCR revealed significantly upregulated retinal enhancer RNA expression in UK-SV2 ROs compared to controls (n¼ 3, mean5 stan-
dard error of the mean, **p % 0.01).
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(Figures 4A and S9). In NL-SV1, the duplication contains
part of the YPEL2 TAD, the boundary to the neighboring
region and GDPD1. This results in the creation of a neo-
TAD that now contains the previously separated YPEL2 en-
hancers and GDPD1 in one domain. To directly investigate
the effect of the SVs in retinal cells, we reprogrammed
dermal fibroblasts from UK-SV2 to iPSC and differentiated
to 3D ROs, thus creating an in vitro model (Supplemental
Information). In this case, the duplicated regions are also
inverted. Hi-C of RP17 ROs (UK-SV2) revealed the creation
of two neo-TADs compared to control ROs (Figure 4B). The
rearrangement of CTCF sites caused by the SV creates
boundaries for two novel domains (neo-TAD 1 and 2)
where neo-TAD 2 contains a duplicated copy of GDPD1
and SMG8 and the retinal enhancers, confirming the
modeling for this SV (Figure 4A). Furthermore, on the basis
of our predictions, neo-TADs are created in each of the
RP17 cases and GDPD1 is predicted to gain ectopic access
to the retinal-specific enhancers (Figures 4A and S9). There-
fore, the potential convergent mechanism for retinal
degeneration is transcriptional activation and expression
of GDPD1 through juxtaposition of retinal TF binding sites
within active compartments bounded by CTCF sites. This
model would also fit with a dominant gain-of-function
mechanism of disease.
Next, we assessed retinal enhancer expression in control
and UK-SV2 ROs by enhancer RNA qPCR (Supplemental
Information). A significant increase of the retinal enhancer
was detected in RP17 ROs (Figure 4C), demonstrating that
this transcriptionally active retinal enhancer in the neo-
TAD could drive retinal expression of GDPD1.Differential Expression of GDPD1 in RP17 iPSC-Derived
Photoreceptor Precursors and 3D Retinal Organoids
Our experimental data and modeling predict GDPD1
enters a neo-TAD with retinal enhancers in all RP17
SVs. An extra copy of YPEL2 enters the neo-TAD of
NL-SV1, and SMG8 enters this domain in UK-SV2 (Fig-
ures 5 and S9).
To experimentally validate the consequence of RP17 SVs
in genomic and cellular context, we performed qPCR to
assess differential expression in PPCs (NL-SV1) and ROs
(UK-SV2). The expression of GDPD1, YPEL2, and SMG8
was compared to controls (Supplemental Information).
In both experimental models, the expression of GDPD1
was significantly increased compared to controls. YPEL2Figure 5. Convergent Mechanism of Ectopic Retinal Enhancer-GD
(A) In wild-type genomic context, YPEL2 expression in retina is driv
boring genes are insulated from retinal enhancer activation.
(B) The NL-SV1 duplication creates a neo-TAD with a full-length copy
specific enhancers to ectopically interact with GDPD1, which drives
(C) qPCR analysis of photoreceptor precursor cells (PPCs) revealed a
controls.
(D) The UK-SV2 duplication and inversion creates a neo-TAD with a
bounded by CTFC sites.
(E) qPCR analysis ROs revealed a significant upregulation ofGDPD1 ex
ROs, mean 5 standard error of the mean, **p % 0.01, ****p % 0.000
The Americanwas increased in NL-SV1 only (Figure 5C), whereas SMG8
was increased in UK-SV2 (Figure 5E), which correlates
with our TAD modeling and Hi-C experimental data for
UK-SV2 ROs (Figured 5B, 5D, and S9). To further explore
the tissue-specific effect of this transcriptional upregula-
tion, we performed the same qPCR assays on fibroblasts
of the same individuals. None of these genes had increased
expression in affected individuals compared to controls
(data not shown).Discussion
Previous genetic studies of adRP-affected families mapping
to the RP17 locus have implicated missense variants in
CA4 as the cause of disease or have been unable to confirm
pathogenicity.7,8 Here, we describe the discovery of SVs as
the cause of adRP at the RP17 locus in a large number of
families, suggesting this is a previously unrecognized
major locus for adRP. Our results show how complex
rearrangements can result in the disruption of 3D genome
architecture, the re-wiring of enhancer-promoter interac-
tions, and consequent gene misexpression.
Following the identification of SVs in NL1 and UK1 via
short-read WGS, our search for similar complex SVs in
the RP17 genomic interval of genetically unexplained
adRP-affected families identified six other complex SVs
that segregated with disease. SVs are a major source of
normal variation in the human genome and are often
benign;27,28 however, none of the RP17 SVs are found in
the population database gnomAD29 or the Database of
Genomic Variants (DGV).30 Although overlapping canon-
ical SVs (deletions and duplications) have been identified,
they do not have breakpoints within the YPEL2-
LINC01476 region, as observed for all RP17 SVs reported
in this study. This is in line with observations that different
SVs can have different consequences depending on the
characteristics of specific SVs in local 3D chromatin and
epigenetic context.31,32
Base level resolution of breakpoint junctions and inter-
rogation of the DNA sequence signatures revealed the
mechanisms of the chromosomal rearrangements. Repeti-
tive elements are key factors in facilitating unequal cross-
over of genomic segments or providing microhomology
that induces fork stalling and subsequent template switch-
ing.33,34 Consistent with this model, repetitive elements
were present in the flanking sequences of breakpointPD1 Interaction Caused by RP17 SVs
en by retinal enhancers in a TAD with CTCF boundaries. Neigh-
of YPEL2, GDPD1, and the retinal enhancers. This enables retinal-
its misexpression.
significant upregulation of GDPD1 in NL-SV1 PPCs compared to
full-length copy of GDPD1 and SMG8 and the retinal enhancers
pression in UK-SV2 ROs compared to controls (n¼ 3 independent
1).
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junctions. In addition, microhomology, larger stretches of
homology, and small insertions-deletions were found at all
breakpoints.34–36 Therefore, repetitive elements may
explain why the RP17 locus is prone to such structural vari-
ation, which is supported by the presence of breakpoint
‘‘hotspots,’’ as seen in LINC01476 intron 2 and YPEL2
intron 4; some breakpoints only differ by a small number
of base pairs (e.g., for UK-SV2 and UK-SV7).
None of the genes implicated in the RP17 SVs have been
previously associated with retinal disease. YPEL2 is ex-
pressed in retina, and single-cell RNA sequencing of human
and primate retina revealed expression in photoreceptors;
the highest expression was in rod photoreceptors.22,23
Although the function of YPEL2 in the retina is unknown,
we show that retinal expression is controlled by a number
of retinal TF binding sites, including NRL, which is predom-
inantly expressed in rod photoreceptors. Furthermore, Hi-C
data show thatYPEL2 and the retinal enhancer binding sites
are insulated from the surrounding region in a structured
YPEL2 TAD in control ROs and other tissues.
Hi-C analyses of UK-SV2 ROs revealed the generation of
neo-TADs, and altered structure and repositioning of the
boundaries enabled GDPD1 promoter-retinal enhancer
contacts and consequent GDPD1 misexpression in the
retina. The molecular disease mechanism in these cases is
similar to the reported duplications at the SOX9/KCNJ2
locus.13 As described for the rearrangements reported
here, the duplications at the SOX9 (MIM: 608160) locus
also encompass a regulatory domain (of SOX9), a boundary
(between the SOX9 and the KCNJ2 [MIM: 600681] TADs),
and the neighboring gene (KCNJ2). This results in the
formation of a neo-TAD containing the SOX9 regulatory
elements and the new target gene (KCNJ2) that are now
free to interact. In the SOX9 case, this leads to misexpres-
sion of KCNJ2 in a SOX9 pattern and consecutive limb
malformation, whereas in the RP-affected individuals,
the interaction of GDPD1 with YPEL2 enhancers leads to
misexpression in the retina. However, in some of the
RP-affected individuals, such as UK-SV2, the situation is
more complex because the duplications are inverted. In-
versions can lead to the exchange of regulatory material
from one end of the breakpoint to the other (also called
TAD-shuffling).12 In UK-SV2, the duplication creates two
neo-TADs, but the content is reorganized by the inversion.
Again, GDPD1 and retinal enhancers are brought together
in one new TAD. Thus, the pathogenetic principle remains
the same because all the RP17 SVs are predicted to create
new TADs allowing access of the retinal enhancers to
GDPD1. This suggests that increased expression of
GDPD1 in photoreceptors is the convergent mechanism
of disease. Consistent with this hypothesis, PPCs from
NL-SV1 and ROs from UK-SV2 showed significant
increased expression of GDPD1 in RP17-affected families
with different SVs compared to controls. In UK-SV2 ROs,
an increased expression of SMG8, which is also introduced
into the active neo-TAD of UK-SV2, was observed.
Conversely, YPEL2 shows upregulation in NL-SV1, which812 The American Journal of Human Genetics 107, 802–814, Novemis in line with the complete duplication of YPEL2 in
NL-SV1. Importantly, qPCR provided evidence for the
increased expression of the retinal enhancer in UK-SV2
ROs and TF binding sites for NRL, which is preferentially
expressed in rod photoreceptors, the primary cell type
affected in RP.
Although increased expression of SMG8, YPEL2, or the
retinal enhancer cannot be excluded from contributing
to the phenotype in individual families, these experi-
mental data support the hypothesis of a convergent mech-
anism ofGDPD1 entry into the active neo-TADwith retinal
enhancers for all eight complex RP17 SVs. This is further
supported by the observation that the two affected individ-
uals in family UK13, who had an earlier age of onset and
more severe phenotype compared to all other families,
have a triplication (UK-SV6) where two copies of GDPD1
are predicted to enter the active neo-TAD.
Our data implicate increased retinal expression of
GDPD1 as a dominant gain-of-function mechanism lead-
ing to adRP. GDPD1 encodes a glycerophosphodiesterase,
which can hydrolyze lysophosphatidylcholine (lyso-PC)
to lysophosphatidic acid (LPA)37 with lysophospholipase
D (lysoPLD) activity on various lysophospholipids.38
GPDP1 is detected at low expression in the healthy retina,
and therefore, increased expression of GDPD1 could lead
to dysregulation of lipid metabolism, which is known to
be critical for photoreceptor function, although the exact
mechanisms of photoreceptor cell death are not
known.39–41 Disruption of lipid metabolism leading to
adRP, combined with the adult age of onset, opens avenues
for therapeutic intervention to preserve vision by restoring
lipid homeostasis.Data and Code Availability
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